Flagship merges two startups to build a $220M Repertoire of T cell tech, therapies
Soon after John Cox took over as CEO at Torque Therapeutics, he reached out to Jose‑Carlos Gutiérrez‑Ramos.
Gutiérrez‑Ramos, who left Synlogic in 2018 to join Flagship Pioneering, was leading a startup in its portfolio named Cogen Immune Medicines. The team there was honing technologies to decipher the immune synapse around T cells — technologies that, Cox figured, could help characterize the T cells and peptides involved in Torque’s cancer therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.